Business Context and Reporting Period
Immunocore Holdings Plc, a foreign private issuer, filed this Form 6-K on May 11, 2022, for the month of May 2022. The filing incorporates by reference the Unaudited Condensed Consolidated Interim Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2022, as well as a press release dated May 11, 2022.
Key Financial Metrics
The provided text serves as a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the incorporated exhibits (99.1 and 99.2) which are not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. Investors must refer to the incorporated Management's Discussion and Analysis (Exhibit 99.2) for comparative operational and financial results.
Guidance, Outlook, and Risks
The filing includes a Cautionary Note on Forward-Looking Statements, warning that actual results may differ materially from expectations due to risks and uncertainties. The Company undertakes no obligation to update these statements except as required by law. Specific risks are referenced in the Company's other SEC filings under "Risk Factors."
Investor Verification Checklist
- Review Exhibit 99.1 for the specific financial figures for the three months ended March 31, 2022.
- Examine Exhibit 99.2 for management's analysis of financial condition and results of operations.
- Read the Press Release (Exhibit 99.3) for any material announcements made on May 11, 2022.
- Consult the Company's Form 20-F for a comprehensive list of risk factors.